CUE-102

N/A

Report date: 2025/07/23 17:56:11

Base Information

Drug NameCUE-102
Drug Alias NameCUE-102CUE-A02LR-19129
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionInterleukin-2 receptor agonistsImmunostimulants
TargetsInterleukin-2 receptor
Therapy Area/IndicationsOvarian NeoplasmsPancreatic NeoplasmsStomach Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCue Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesLg Chemical LtdCue Biopharma Inc
Inactive CompaniesN/A
Active IndicationsOvarian NeoplasmsPancreatic NeoplasmsStomach Neoplasms +[6] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A